Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy (Q35045474)

6 August 2017

1 reference

title

Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy (English)

1 reference

6 August 2017

chronic myeloid leukemia

0 references

1 reference

Brian J Druker

1

1 reference

6 August 2017

1 September 2002

1 reference

European Journal of Cancer

6 August 2017

1 reference

6 August 2017

38 Suppl 5

1 reference

6 August 2017

S70-6

1 reference

6 August 2017

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980606-2

7 January 2021

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980606-2

7 January 2021

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980606-2

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980606-2

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980606-2

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980606-2

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980606-2

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980606-2

7 January 2021

Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980606-2

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980606-2

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980606-2

7 January 2021

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980606-2

7 January 2021

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980606-2

7 January 2021

10.1016/S0959-8049(02)80606-2

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12528776